The abstract is read at the publisher; the summary is JClub's.
In a Phase 1 trial in 212 healthy adults, an 8-week dosing interval for ARCT-2304 produced higher and more durable HA inhibition and anti-NA antibody levels than a 4-week schedule at 6–7 months.
- Why it matters: Pandemic H5N1 remains a persistent threat, and conventional vaccine timelines can be slow, so approaches that enable rapid development and durable protection are needed.
- What they did: In an observer-blind, randomized dose-finding study (NCT06602531), participants received two ARCT-2304 doses (1.5, 5, or 12 mcg) on 4- or 8-week schedules, with immunogenicity measured 28 days post-second dose and followed through 6–7 months.
- The result: ARCT-2304 was well-tolerated with mostly mild-to-moderate transient, dose-dependent solicited AEs and induced robust HA and NA humoral responses, supporting further development of sa-mRNA for pandemic influenza preparedness.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.